{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00025964", "CSN": null, "TRF": "ORD_1537947_01", "MRN": "48288502", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1257550", "clinicalId": "1258920", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1537947_01", "SampleName": "US1470784.01", "Version": "0", "Sample": {"FM_Id": "ORD_1537947_01", "SampleId": "US1470784.01", "BlockId": "S111-53719I", "TRFNumber": "ORD_1537947_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_01_05", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10012", "MRN": "48288502", "FullName": "\u6797\u6709\u798f", "FirstName": "Yu Fu", "LastName": "Lin", "SubmittedDiagnosis": "Brain glioblastoma (GBM)", "Gender": "Male", "DOB": "1946_09_10", "OrderingMD": "\u5289\u5cfb\u5b87", "OrderingMDId": "109266", "Pathologist": "\u6797\u58eb\u5091", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2022_12_21", "ReceivedDate": "2023-01-19 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": {"PertinentNegative": {"Gene": "IDH1"}}, "Summaries": {"alterationCount": "20", "clinicalTrialCount": "19", "resistiveCount": "0", "sensitizingCount": "7"}, "VariantProperties": {"VariantProperty": [{"geneName": "BCL6", "isVUS": "true", "variantName": "P472R"}, {"geneName": "BRIP1", "isVUS": "true", "variantName": "S1001N"}, {"geneName": "CCNE1", "isVUS": "true", "variantName": "R27H"}, {"geneName": "GNAS", "isVUS": "true", "variantName": "R16C"}, {"geneName": "MAPK1", "isVUS": "true", "variantName": "N238K"}, {"geneName": "MRE11A", "isVUS": "true", "variantName": "G409del"}, {"geneName": "PIK3C2B", "isVUS": "true", "variantName": "S20_R21del"}, {"geneName": "PTEN", "isVUS": "true", "variantName": "L152Q"}, {"geneName": "ROS1", "isVUS": "true", "variantName": "D2213E"}, {"geneName": "SGK1", "isVUS": "true", "variantName": "H72R"}, {"geneName": "TGFBR2", "isVUS": "true", "variantName": "rearrangement"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "EGFR", "Include": "true", "Alterations": {"Alteration": {"Name": "P596L", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "8.16", "isEquivocal": "false", "name": "P596L"}}, "Interpretation": "EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide (Ciardiello and Tortora, 2008; 18337605). EGFR mutations that have been characterized in biochemical assays to be activating, as observed here, are predicted to confer sensitivity to EGFR_targeted therapies (Foster et al., 2010; 20942962, Cai et al., 2008; 18193092, Stabile et al., 2005; 15735034, Zhang et al., 2006; 17409930, Siegfried et al., 2012; 22258476, ManChon et al., 2014; 24743239, Cho et al., 2014; 24894453, Hama et al., 2009; 19726454, Tam et al., 2009; 19671738, Kancha et al., 2009; 19147750, Chen et al., 2006; 16205628, Lee et al., 2006; 17177598, Ymer et al., 2011; 24212795, Razis et al., 2009; 19789313, Wang et al., 2011; 21532887, Cai et al., 2008; 18193092, Kim et al., 2019; 31290142, Sueangoen et al., 2020; 32190291, Lundby et al., 2019; 31585087). EGFR alterations have been reported in 13.2% of anaplastic astrocytomas, 5.3_15.9% of glioblastoma multiformes (GBMs), and 0% of pilocytic astrocytomas in several genomic studies of CNS tumors (cbio_Jonsson et al., 2019; 31263031, cbio_Brennan et al., 2013; 24120142, cbio_Ceccarelli et al., 2016; 26824661, cbio_Thomas et al., 2017; 28472509). In GBMs, Missense mutations in the EGFR extracellular domain have been found in 10_15% of cases and approximately half have a low_level amplification of the mutated allele (Lee et al., 2006; 17177598, Vivanco et al., 2012; 22588883). In a study of IDH_wildtype GBM samples, EGFR alterations were detected in 50% (117/232) of IDH_wildtype GBM samples analyzed, including 41% (95/232) with a co_occurring EGFR amplification and mutation, 26% (61/232) with an EGFR domain truncation event, such as EGFRvIII, and 2.2% (5/232) with an EGFR fusion event (Yan et al. 2020; DOI:10.1200/PO.19.00385). No definitive correlation has been identified between EGFR amplification and length of survival in patients with GBM (Srividya et al., 2010; 20702468, Das et al., 2011; 20888234); however, EGFR amplification has been associated with prolonged survival in patients over the age of 60 with GBM (Smith et al., 2001; 11504770). For patients with non_small cell lung cancer (NSCLC), EGFR activating mutations may predict sensitivity to EGFR\u2013TKIs, including erlotinib (Rosell et al., 2011; 22285168), gefitinib (Douillard et al., 2014; 24263064, Hayashi et al., 2020; 32673682, Cao et al., 2018; 29780256, Yang et al., 2011; 21422421), afatinib (Sequist et al., 2013; 23816960, Bao_Dong Qin et al., 2018; 30127622, Frega et al., 2016; 27131295, Long et al., 2020; 33116645), dacomitinib (Mok et al., 2018; 29864379), and osimertinib (Janne et al., 2015; 25923549, Bao_Dong Qin et al., 2018; 30127622); however, the data for patients with other tumor types are limited (Hong et al., 2020; 32749686, Kim et al., 2015; 26462025, Kim et al., 2015; 25424851, Mondal et al., 2020; 32303840, Cavalieri et al., 2018; 29734047, Chi et al., 2020; 32923886, Audet et al., 2013; ASCO Abstract 6041). Patients with EGFR_mutated bithalamic glioma have reported responses to osimertinib (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). In a case series of 11 patients with bithalamic gliomas with EGFR mutations, EGFR inhibitors, including osimertinib, showed improved survival; however, it showed a lack of significant clinical responses (Mondal et al., 2020; 32303840). On the basis of preclinical data, EGFR mutations confer sensitivity to EGFR inhibitors, including osimertinib (Mondal et al., 2020; 32303840).", "Include": "true", "ClinicalTrialNote": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Osimertinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Osimertinib is an irreversible EGFR TKI that is selective for EGFR TKI_sensitizing mutations and the EGFR T790M mutation. It is FDA approved in various treatment settings for patients with non_small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions, exon 21 L858R mutations, or T790M mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> EGFR TKI_sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non_small cell lung cancer (Janne et al., 2015; 25923549, Soria et al., 2018; 29151359, Alanazi et al., 2020; 33318755, Kim et al., 2021; DOI: 10.1200/PO.20.00296, Wang et al., 2018; 30255937). EGFR mutations may confer sensitivity to osimertinib on the basis of clinical responses to the third_generation TKI osimertinib for patients with EGFR_mutated glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677) and additional clinical studies suggesting clinical benefit for these patients (Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). </p> <p><b>Supporting Data:</b> Clinical benefit from osimertinib has been observed for cases of pediatric and adult patients with EGFR_altered glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Cardona et al., 2021; 34498213, Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). Osimertinib has been studied primarily for the treatment of EGFR_mutated NSCLC. The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first_line osimertinib significantly increased both median PFS (mPFS; 18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced non_small cell lung cancer (NSCLC) and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858) (Soria et al., 2018; 29151359, Ramalingam et al., 2019; 31751012). In the Phase 3 ADAURA study, patients with early_stage (IB/II/IIIA) EGFR_mutated NSCLC experienced longer disease_free survival on osimertinib compared with placebo in the adjuvant setting (65.8 vs. 28.1 months, HR=0.27) (Tsuboi et al., 2022; ESMO Abstract LBA47). A Phase 1 study reported that T790M_negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months (Janne et al., 2015; 25923549). A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR_mutated, T790M_negative NSCLC reported an ORR of 19% (4/21), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 2 study of osimertinib for EGFR_TKI_naive patients with metastatic or recurrent NSCLC and uncommon EGFR mutations reported a 50% (18/36) ORR and an 89% (32/36) DCR with a median PFS of 8.2 months and a median duration of response of 11.2 months; patients harboring L861Q, G719X, or S768I mutations had ORRs of 78% (7/9), 53% (10/19), and 38% (3/8), respectively (Cho et al., 2020; 31825714). A Phase 2 trial of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with untreated advanced non_small cell lung cancer (NSCLC) harboring EGFR del19 or L858R reported no difference in ORR (82% vs 86%) and median PFS (22.1 vs 20.2 months, HR 0.862 p=0.213) (Kenmotsu et al., 2022; 35636696). The Phase 2 BOOSTER study of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with advanced NSCLC with EGFR_sensitizing mutations (exon 19 del or L858R) and L790M at progression on prior EGFR TKI reported no difference in ORR (55% vs 55%), median OS (24.0 vs 24.3 months, HR 1.03 p=0.91), or median PFS (15.4 vs 12.3 months, HR 0.96 p=0.83), although improved PFS was observed for the combination in the subgroup of current or former smokers (16.5 vs 8.4, HR 0.52) while nonsmokers had no benefit (HR 1.47) (Soo et al., 2021; ESMO Abstract VP3_2021). The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR_mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively (Oxnard et al., 2020; 32139298). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Gefitinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non_small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR_mutated non_small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy (Han et al., 2012; 22370314, Maemondo et al., 2010; 20573926, Mitsudomi et al., 2010; 20022809, Mok et al., 2009; 19692680, Petrelli et al., 2011; 22056888, Qi et al., 2015; 25329826, Zhao et al., 2015; 25546556), and responses have been reported for patients with EGFR_rearranged NSCLC (Wang et al., 2018; 30255937, Baik et al., 2015; 26398831). </p> <p><b>Supporting Data:</b> A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). A Phase 2 clinical study of gefitinib in patients with high_grade glioma (including GBM, anaplastic astrocytoma, and oligodendroglioma) reported 18% (5/28) disease stabilization; efficacy was not correlated with EGFR expression (Franceschi et al., 2007; 17353924). However, a Phase 1/2 clinical trial of gefitinib combined with radiotherapy in 178 patients with GBM reported no overall survival benefit of added gefitinib, and EGFR expression was found to be of no prognostic value for patients treated with gefitinib plus radiotherapy (Chakravarti et al., 2013; 23182702). A Phase 2 trial of preoperative gefitinib treatment in patients with recurrent GBM reported that although EGFR phosphorylation was decreased in treated patients as compared to the control group, measurement of 12 downstream molecules revealed no significant changes (Hegi et al., 2011; 21471286). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Erlotinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Erlotinib is a small_molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non_small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first_line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression (Cappuzzo et al., 2010; 20493771, Rosell et al., 2012; 22285168, Zhong et al., 2019; 31194613, Petrelli et al., 2011; 22056888). </p> <p><b>Supporting Data:</b> In the MyPathway Phase 2a basket study for advanced solid tumors, 1 of 9 patients with EGFR activation mutations responded to erlotinib monotherapy; the responding patient had urethral adenocarcinoma (Hainsworth et al., 2018; 29320312). A patient with EGFR_mutated metastatic lacrimal gland adenoid cystic carcinoma experienced clinical benefit from erlotinib treatment that was ongoing at 14 months (Nie et al., 2018; 29998897). A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). In a Phase 2 study of 65 patients with GBM or gliosarcoma, treatment with erlotinib, temozolomide, and radiotherapy resulted in longer progression_free survival relative to a historical control study utilizing a regimen of temozolomide and radiotherapy alone (19.3 months vs. 14.1 months)(Prados et al., 2009; 19075262). However, in a Phase 1/2 trial of erlotinib monotherapy in 11 patients with relapsed or refractory GBM or anaplastic astrocytoma, all patients showed disease progression and the drug showed significant toxicity (Kesavabhotla et al., 2012; 22946346). In addition, a Phase 2 trial of patients with recurrent or progressive GBM treated with erlotinib and sorafenib did not meet its objective of a 30% increase in overall survival time compared with historical controls; sorafenib was found to increase erlotinib clearance (Peereboom et al., 2013; 23328813). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03783403", "Include": "true"}, {"nctId": "NCT04946968", "Include": "true"}, {"nctId": "NCT04670679", "Include": "true"}, {"nctId": "NCT04616196", "Include": "true"}, {"nctId": "NCT04720976", "Include": "true"}, {"nctId": "NCT02800486", "Include": "true"}, {"nctId": "NCT02861898", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "KIT", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "KIT (also called c_KIT) encodes a cell surface tyrosine kinase receptor that, upon ligand binding and dimerization, activates the PI3K_AKT and RAS_MAPK signaling pathways (Linnekin, 1999; 10582339). KIT aberrations, including point mutations, translocations, amplification, and overexpression, have been associated with various malignancies, and KIT is considered an oncoprotein (Fletcher, 2004; 15175998). KIT has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). In the TCGA datasets, KIT amplification has been reported in 2.5% of lower grade gliomas (grades 2 and 3)(Cancer Genome Atlas Research Network., 2015; 26061751) and 9.2% of glioblastomas (Grade 4 astrocytoma)(cBio_Brennan et al., 2013; 24120142). KIT amplification has been variously reported in 4_47% of glioblastomas in the scientific literature (Nobusawa et al., 2011; 21382095, Joensuu et al., 2005; 16021678, Burford et al., 2013; 23990986). Amplification of KIT has been strongly correlated with the presence of KDR and/or PDGFRA amplification in glioblastoma (Joensuu et al., 2005; 16021678, Holtkamp et al., 2007; 17504929, Puputti et al., 2006; 17189383). One study found no correlation between KIT amplification and overall survival in patients with glioblastoma, while a separate study reported that overexpression of KIT was associated with tumor grade and shorter survival in patients with malignant glioma (Nobusawa et al., 2011; 21382095, Skardelly et al., 2009; 19701495). On the basis of clinical evidence, primarily in gastrointestinal stromal tumor (GIST), melanoma, AML, and systemic mastocytosis, KIT activating alterations are associated with sensitivity to TKIs including imatinib, sunitinib, sorafenib, dasatinib, nilotinib, pazopanib, regorafenib, ponatinib, midostaurin, apatinib, avapritinib, and ripretinib (Heinrich et al., 2014; ASCO Abstract 10506, Heinrich et al., 2017; ASCO Abstract 11011, DeAngelo et al., 2017; ASH Abstract 2, Evans et al., 2017; 29093181, Abbaspour Babaei et al., 2016; 27536065, Ramaswamy et al., 2016; 27563456, Demetri et al., 2013; 23177515, Gotlib et al., 2016; 27355533, Jawhar et al., 2017; 28424161, Xu et al., 2014; 25031773, Gotlib et al., 2005; 15972446, George et al., 2018; ASCO Abstract 11511, Luo et al., 2017; 29066909, Janku et al., 2022; 35753087). The use of mTOR inhibitors as an alternative therapeutic strategy has demonstrated limited success in KIT_mutated, imatinib_resistant melanoma, with 1 PR and 3 SD observed for 4 patients treated with everolimus (Si et al., 2012; ASCO Abstract 8562, Si et al., 2012; 22162580). However, no responses were observed for 10 patients with mastocytosis following everolimus monotherapy, with 8/10 patients harboring the KIT D816V mutation (Parikh et al., 2010; 20038218). The role of KIT amplification as a biomarker for response to mTOR inhibitors has not been investigated (PubMed, Mar 2022). Clinical benefit has been observed for patients with KIT amplified or overexpressing tumors following treatment with imatinib (Wei et al., 2019; 30075827, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685, Guo et al., 2011; 21690468, Debiec_Rychter et al., 2005; 15685537, DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Hotte et al., 2005; 15659505, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Reardon et al., 2009; 19904263), nilotinib (Lee et al., 2015; 26424760), sorafenib (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), and sunitinib (Minor et al., 2012; 22261812, Mahipal et al., 2012; 23114504), suggesting that KIT amplification may be sensitive to these inhibitors. However, evidence demonstrating clinical benefit for regorafenib, dasatinib, pazopanib, or ponatinib in the context of KIT amplified or overexpressing tumors is limited.", "Include": "true", "ClinicalTrialNote": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Sunitinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Sunitinib is a small_molecule tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, KIT, FLT3, CSF_1R, and RET. It is FDA approved for the treatment of advanced or metastatic pancreatic neuroendocrine tumors, gastrointestinal stromal tumors (GISTs) in patients who have progressed on or are intolerant to imatinib, and advanced renal cell carcinoma (RCC) as well as for the adjuvant treatment of patients at high risk of recurrent RCC after nephrectomy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Minor et al., 2012; 22261812, Heinrich et al., 2008; 18955458, Buchbinder et al., 2015; 26264378, Reichardt et al., 2016; 26772734, Hirai et al., 2016; 27073655, Goemans et al., 2010; 20435347) or KIT_expressing tumors (Mahipal et al., 2012; 23114504, Minor et al., 2012; 22261812), KIT activating alterations may predict sensitivity to sunitinib. </p> <p><b>Supporting Data:</b> Phase 2 clinical trials of sunitinib in glioblastoma have reported no significant improvement in clinical outcome (Pan et al., 2012; 22832897, Kreisl et al., 2013; 23086433). A Phase 2 trial that examined sunitinib treatment followed by radiation therapy in patients with glioblastoma reported a median progression_free survival (PFS) of 7.7 weeks, and a median overall survival (OS) of 12.8 weeks; 83.3% (10/12) of patients experienced neurological deterioration prior to radiation therapy (Bala\u00f1a et al., 2014; 24424564). Another Phase 2 study that examined daily sunitinib treatment in patients with glioblastoma reported no objective response in any of the 40 patients, with a median PFS of 2.2 months and a median OS of 9.2 months; five patients in the study had stable disease for more than six months (Hutterer et al., 2014; 24311637). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Sorafenib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Quint\u00e1s_Cardama et al., 2008; 18936790, Bisagni et al., 2009; 19461405, Handolias et al., 2010; 20372153, Disel et al., 2011; 20970876, Park et al., 2012; 22270258, Catania et al., 2014; 24855380, Guo et al., 2007; 17699867, Hu et al., 2008; 18483300) or KIT_expressing tumors (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), KIT activating alterations may predict sensitivity to sorafenib. </p> <p><b>Supporting Data:</b> Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM) (Zustovich et al., 2013; 23898124; Reardon et al., 2011; 20443129). A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival (Lee et al., 2012; 23099651). A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib (Peereboom et al., 2013; 23328813). In a Phase 1 trial in patients with high_grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone (Hottinger et al., 2014; 24786603). In a clinical study of sorafenib in pediatric patients with low_grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates (Karajannis et al., 2014; 24803676). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Imatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively (Hassler et al., 2014; 25674429). However, other Phase 2 clinical trials of imatinib have reported no anti_tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4% (Razis et al., 2009; 19789313, Reardon et al., 2009; 19904263). In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low_grade glioma, but had negligible antitumor activity (Reardon et al., 2012; 22371319). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Nilotinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Nilotinib targets tyrosine kinases such as ABL (including BCR_ABL), PDGFRs, KIT, CSF1R, DDR1, and DDR2. It is FDA approved to treat newly diagnosed pediatric or adult patients with Philadelphia chromosome_positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with Ph+ CML in chronic or accelerated phase with resistance or intolerance to prior therapy including imatinib, and pediatric patients with Ph+ CML in chronic phase with resistance or intolerance to prior tyrosine_kinase inhibitor therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Lee et al., 2015; 26424760, Carvajal et al., 2015; 25695690, Hochhaus et al., 2015; 26002753, Blay et al., 2015; 25882987, Kaijimoto et al., 2015; 26722383), KIT_amplified (Lee et al., 2015; 26424760), or KIT_expressing tumors (Sako et al., 2014; 25221952), KIT activating alterations may confer sensitivity to nilotinib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of nilotinib for the treatment of CNS tumors are limited (PubMed, Jul 2022). Nilotinib has been primarily investigated as a therapeutic option for the treatment of CML or gastrointestinal stromal tumors (GIST). In the context of CML, a Phase 3 clinical trial of Ph+ patients treated with imatinib or nilotinib (300 mg or 400 mg) reported progression_free survival (PFS) rates of 93% and 97_98% and overall survival (OS) rates of 93% and 94_97%, respectively, at 4 years (Hughes et al., 2014; 24335106). For imatinib_resistant Japanese patients with CML, a Phase 2 trial reported a 47.8% major medical response rate to treatment with nilotinib at 12 months (Takahashi et al., 2014; 24650752). A Phase 3 clinical trial of single_agent nilotinib in 240 patients with advanced GIST who failed prior treatment with imatinib or sunitinib reported no significant difference in progression_free survival between nilotinib and the best supportive care, but did report increased overall survival for nilotinib_treated patients (Reichardt et al., 2012; 22357255). A Phase 2 trial has shown that nilotinib was well tolerated and suggested it may be particularly useful for treating patients with GIST harboring mutations in KIT exon 17 (Cauchi et al., 2012; 22119758). Preclinical, cell_based assays have reported efficacy for nilotinib alone and in combination with additional therapies in the context of leiomyosarcoma and synovial sarcoma (Villar et al., 2012; 22662203). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT05024214", "Include": "true"}, {"nctId": "NCT05098847", "Include": "true"}, {"nctId": "NCT03564691", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04008797", "Include": "true"}, {"nctId": "NCT04977453", "Include": "true"}, {"nctId": "NCT03025893", "Include": "true"}, {"nctId": "NCT04729348", "Include": "true"}, {"nctId": "NCT02379416", "Include": "true"}, {"nctId": "NCT05064280", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MTAP", "Include": "true", "Alterations": {"Alteration": {"Name": "loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss"}}, "Interpretation": "MTAP encodes S_methyl_5 _thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity (Limm et al., 2016; 27479139, Tang et al., 2014; 25387827). Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment (Kirovski et al., 2011; 21356366, Limm et al., 2013; 23265702, Stevens et al., 2009; 19097084), thereby reducing intracellular arginine methylation (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360) and altering cell signaling (Limm et al., 2014; 25087184, Stevens et al., 2009; 19097084). MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co_deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized. MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers (Wei et al., 2016; 27929028, Zhao and Zhao, 2016; 27556634); such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma (Kirovski et al., 2011; 21356366), gastrointestinal stromal tumors (Huang et al., 2009; 19887491), mantle cell lymphoma (MCL)(Marce et al., 2006; 16778103), melanoma (Meyer et al., 2010; 20500769, Wild et al., 2006; 16618867), gastric cancer (Kim et al., 2011; 21412930), myxofibrosarcoma (Li et al., 2014; 25426549), nasopharyngeal carcinoma (He et al., 2015; 26656376), ovarian carcinoma (Wei et al., 2016; 27929028) and non_small cell lung cancer (Su et al., 2014; 24969958). MTAP loss was not prognostic in pediatric B_cell acute lymphocytic leukemia (Mirebeau et al., 2006; 16818274) or in astrocytoma (Becker et al., 2015; 26088413). However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples (Snezhkina et al., 2016; 27433286), and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM (Bistulfi et al., 2016; 26910893). Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma (Antonopoulou et al., 2015; 25407435, Mccioni et al., 2013; 23816148), esophageal cancer (Hyland et al., 2016; 26635288, Lin et al., 2017; 27960044), osteosarcoma (Zhi et al., 2016; 27994653), and CRC (Gu et al., 2013; 23361049). MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A (Kalev et al., 2021; 33450196, Heist et al., 2019; AACR_NCI_EORTC Abstract B116, Marjon et al., 2016; 27068473) or PRMT5 inhibition (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360). A Phase 1 trial of MAT2A inhibitor AG_270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss (Heist et al., 2019; AACR_NCI_EORTC Abstract B116). Preclinical data suggest that MTAP loss sensitizes cells to S_adenosyl_L_methionine (SAM)_competitive PRMT5 inhibitors (Guccione and Richard, 2019; 31350521), dual PRMT1 and PRMT5 inhibitors (Fedoriw et al., 2019; 31257072, Srour et al., 2019; 31287990, Gao et al., 2019; 30916320), and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S_methyl_5 _thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193 (Smith et al., 2022; 35041419, Briggs et al., 2022; AACR Abstract 3941). In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA (Hansen et al., 2019; 31040154, Tang et al., 2018; 29844120, Munshi et al., 2014; 24928612, de Oliveira et al., 2016; 26751376, Lubin and Lubin, 2009; 19478948, Tang et al., 2012; 22825330, Collins et al., 2012; 22252602, Bertino et al., 2011; 21301207, Coulthard et al., 2011; 21282358, Miyazaki et al., 2007; 17912432, Efferth et al., 2002; 11987241). A Phase 2 study of L_alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP_deficient cancers reported no responses and SD for 24% (13/55) of patients (Kindler et al., 2009; 18618081). Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed (Alhalabi et al., 2022; 35379845).", "Include": "true", "ClinicalTrialNote": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": {"nctId": "NCT05245500", "Include": "true"}}}}, "ReferenceLinks": null}, {"Name": "PDGFRA", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). Amplification of PDGFRA, frequently occurring with amplification of the genes KDR and KIT, has been associated with increased PDGFRA expression (Burford et al., 2013; 23990986, Flavahan et al., 2016; 26700815, Roszik et al., 2016; 26787600, Verhaak et al., 2010; 20129251) and poor prognosis (Burford et al., 2013; 23990986, Koschmann et al., 2016; 27582545, Phillips et al., 2013; 23438035, Puget et al., 2012; 22389665) in some subtypes of glioma. PDGFRA amplification has been suggested to be more common in higher grade astrocytomas than in lower grade astrocytomas; studies have reported PDGFRA amplification in 16.3% (27/166) of Grade 2 astrocytomas and in 23.6% (91/386) of Grade 3 and 4 astrocytomas analyzed (Holtkamp et al., 2007; 17504929, Phillips et al., 2013; 23438035, Motomura et al., 2013; 23242283). PDGFRA amplification has been reported in 5.2_33% of glioblastoma cases (cBio_Brennan et al., 2013; 24120142, Phillips et al., 2013; 23438035, Sottoriva et al., 2013; 23412337, Nobusawa et al., 2011; 21382095, Joensuu et al., 2005; 16021678, Alentorn et al., 2012; 23074200). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co_expression of these genes was an indicator of poor prognosis in a GBM patient cohort (Song et al., 2018; 29888103). Amplification of PDGFRA has been associated with tumor grade and poor progression_free and overall survival in patients with glioblastoma (Alentorn et al., 2012; 23074200, Sottoriva et al., 2013; 23412337, Phillips et al., 2013; 23438035). In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutation in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis (Phillips et al., 2013; 23438035). Amplification of PDGFRA has also been strongly correlated with the presence of KDR and/or KIT amplification in glioblastomas, as well as with EGFR amplification (Joensuu et al., 2005; 16021678, Holtkamp et al., 2007; 17504929, Puputti et al., 2006; 17189383, Szerlip et al., 2012; 22323597). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Koc\u00e1kov\u00e1 et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515).", "Include": "true", "ClinicalTrialNote": "PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Imatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively (Hassler et al., 2014; 25674429). However, other Phase 2 clinical trials of imatinib have reported no anti_tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4% (Razis et al., 2009; 19789313, Reardon et al., 2009; 19904263). In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low_grade glioma, but had negligible antitumor activity (Reardon et al., 2012; 22371319). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": {"nctId": "NCT01738139", "Include": "true"}}}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (6%) (Jonsson et al., 2019; 31263031). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF_encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (6%) (Jonsson et al., 2019; 31263031). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF_encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TERT", "Include": "true", "Alterations": {"Alteration": {"Name": "promoter _124C>T", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "20.9", "isEquivocal": "false", "name": "promoter _124C>T"}}, "Interpretation": "Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80_90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at _124 bp and _146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions \u2013124/\u2013125 bp and \u2013138/\u2013139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been reported in 51_59% of gliomas (Killela et al., 2013; 23530248, Killela et al., 2014; 24722048), most frequently in glioblastoma (GBM, 54_84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25_31%) but less frequently in lower grade astrocytomas (10_18%) and in only 1% of ependymomas (Nonoguchi et al., 2013; 23955565, Liu et al., 2013; 23603989, Koelsche et al., 2013; 24154961, Killela et al., 2013; 23530248, Killela et al., 2014; 24722048). In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58_83%) (Nonoguchi et al., 2013; 23955565, Killela et al., 2013; 23530248). One study detected TERT promoter mutations in 78% (181/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM (Arita et al., 2013; 23764841). TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH_positive secondary GBM (Killela et al., 2013; 23530248, Nonoguchi et al., 2013; 23955565, Reitman et al., 2013; 24217890, Arita et al., 2013; 23764841). In the context of IDH_wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v1.2022). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor_associated antigen and antisense oligonucleotide_ or peptide_based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti_CTLA_4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non_small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017). TERT mutations are associated with 1p/19q co_deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX_wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v1.2022)(Weller et al., 2020; 33293629). The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2_wildtype tumors (NCCN CNS Cancers Guidelines, v1.2022) (Louis et al., 2021; 34185076).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "08", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "08"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "EGFR", "Alteration": "P596L", "Title": "A Study of CC_95251, a Monoclonal Antibody Directed Against SIRP\u03b1, in Subjects With Advanced Solid and Hematologic Cancers", "StudyPhase": "PHASE 1", "Target": "CD20, EGFR, SIRP_alpha", "Locations": "Seoul (Korea, Republic of), Heidelberg (Australia), Melbourne (Australia), Manchester (United Kingdom), Edmonton (Canada), Rouen (France), Oregon, Marseille (France), Creteil (France), Nantes Cedex 01 (France)", "NCTID": "NCT03783403", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "P596L", "Title": "Phase_2 Dacomitinib Study on Patients With EGFR_Driven Advanced Solid Tumours With Low EGFR_AS1 IncRNA Expr or Other Novel Emerging Biomarkers", "StudyPhase": "PHASE 2", "Target": "ERBB4, EGFR, ERBB2", "Locations": "Singapore (Singapore)", "NCTID": "NCT04946968", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "P596L", "Title": "A Dose Escalation/Expansion Study of ERAS_601 in Patients With Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "SHP2, EGFR", "Locations": "Perth (Australia), Melbourne (Australia), Nevada, California, Texas, Massachusetts, New York, Tennessee, Florida", "NCTID": "NCT04670679", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "P596L", "Title": "Study of NKTR 255 in Combination With Cetuximab in Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "EGFR", "Locations": "California, Montana, Arizona, Minnesota, Illinois, Michigan, Texas, New York", "NCTID": "NCT04616196", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "P596L", "Title": "JAB_3312 Activity in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MEK, SHP2, PD_1, EGFR, KRAS", "Locations": "Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut", "NCTID": "NCT04720976", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "P596L", "Title": "Super Selective Intra_arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA", "StudyPhase": "PHASE 2", "Target": "EGFR", "Locations": "New York", "NCTID": "NCT02800486", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "P596L", "Title": "Super_selective Intra_arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma", "StudyPhase": "PHASE 1/2", "Target": "EGFR", "Locations": "New York", "NCTID": "NCT02861898", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PD_L1, FGFRs, RET, PDGFRA, VEGFRs, KIT, FLT3, CSF1R", "Locations": "Hangzhou (China), Shanghai (China), Dongguan (China), Guangzhou (China), Zhuhai (China), Benbu (China), Zhengzhou (China), Jinan (China), Dalian (China), Tianjin (China)", "NCTID": "NCT05024214", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors", "StudyPhase": "PHASE 2", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Shanghai (China)", "NCTID": "NCT05098847", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)", "StudyPhase": "PHASE 1", "Target": "ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Shanghai (China), Seoul (Korea, Republic of), Brisbane (Australia), Liverpool (Australia), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Haifa (Israel), Warszawa (Poland), Gdansk (Poland)", "NCTID": "NCT03564691", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor", "StudyPhase": "PHASE 1", "Target": "CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Kurume (Japan), Matsuyama (Japan), Seodaemun (Korea, Republic of), Osakasayama (Japan), Nagoya (Japan), Chuo_Ku (Japan), Koto_ku (Japan), Chiba (Japan), Kashiwa (Japan), Hidaka (Japan)", "NCTID": "NCT04008797", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "GI_101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1, CTLA_4", "Locations": "Daejeon (Korea, Republic of), Suwon_si (Korea, Republic of), Seoul (Korea, Republic of)", "NCTID": "NCT04977453", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "A Phase II/III Study of High_dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme", "StudyPhase": "PHASE 2/3", "Target": "FLT3, VEGFRs, CSF1R, KIT, RET", "Locations": "Groningen (Netherlands), Nijmegen (Netherlands), Amsterdam (Netherlands)", "NCTID": "NCT03025893", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Pembrolizumab And Lenvatinib In Leptomeningeal Metastases", "StudyPhase": "PHASE 2", "Target": "PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET", "Locations": "Massachusetts", "NCTID": "NCT04729348", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors", "StudyPhase": "PHASE 1", "Target": "ABL, KIT", "Locations": "Maryland", "NCTID": "NCT02379416", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "KIT", "Alteration": "amplification", "Title": "Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases", "StudyPhase": "PHASE 2", "Target": "PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET", "Locations": "Texas", "NCTID": "NCT05064280", "Note": "KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss", "Title": "Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Colorado, Massachusetts, New York, Tennessee, Texas", "NCTID": "NCT05245500", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "amplification", "Title": "Ipilimumab and Imatinib Mesylate in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "KIT, ABL, CTLA_4", "Locations": "Texas", "NCTID": "NCT01738139", "Note": "PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "27479139", "FullCitation": "Limm K, et al. PLoS ONE (2016) pmid: 27479139", "Include": "true"}, {"number": "1", "ReferenceId": "25387827", "FullCitation": "Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827", "Include": "true"}, {"number": "2", "ReferenceId": "21356366", "FullCitation": "Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366", "Include": "true"}, {"number": "3", "ReferenceId": "23265702", "FullCitation": "Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702", "Include": "true"}, {"number": "4", "ReferenceId": "19097084", "FullCitation": "Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084", "Include": "true"}, {"number": "5", "ReferenceId": "27068473", "FullCitation": "Marjon K, et al. Cell Rep (2016) pmid: 27068473", "Include": "true"}, {"number": "6", "ReferenceId": "26912361", "FullCitation": "Mavrakis KJ, et al. Science (2016) pmid: 26912361", "Include": "true"}, {"number": "7", "ReferenceId": "26912360", "FullCitation": "Kryukov GV, et al. Science (2016) pmid: 26912360", "Include": "true"}, {"number": "8", "ReferenceId": "25087184", "FullCitation": "Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184", "Include": "true"}, {"number": "9", "ReferenceId": "27929028", "FullCitation": "Wei R, et al. Sci Rep (2016) pmid: 27929028", "Include": "true"}, {"number": "10", "ReferenceId": "27556634", "FullCitation": "Zhao M, et al. BMC Genomics (2016) pmid: 27556634", "Include": "true"}, {"number": "11", "ReferenceId": "19887491", "FullCitation": "Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491", "Include": "true"}, {"number": "12", "ReferenceId": "16778103", "FullCitation": "Marc\u00e9 S, et al. Clin. Cancer Res. (2006) pmid: 16778103", "Include": "true"}, {"number": "13", "ReferenceId": "20500769", "FullCitation": "Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769", "Include": "true"}, {"number": "14", "ReferenceId": "16618867", "FullCitation": "Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867", "Include": "true"}, {"number": "15", "ReferenceId": "21412930", "FullCitation": "Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930", "Include": "true"}, {"number": "16", "ReferenceId": "25426549", "FullCitation": "Li CF, et al. Oncotarget (2014) pmid: 25426549", "Include": "true"}, {"number": "17", "ReferenceId": "26656376", "FullCitation": "He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376", "Include": "true"}, {"number": "18", "ReferenceId": "24969958", "FullCitation": "Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958", "Include": "true"}, {"number": "19", "ReferenceId": "16818274", "FullCitation": "Mirebeau D, et al. Haematologica (2006) pmid: 16818274", "Include": "true"}, {"number": "20", "ReferenceId": "26088413", "FullCitation": "Becker AP, et al. Pathobiology (2015) pmid: 26088413", "Include": "true"}, {"number": "21", "ReferenceId": "27433286", "FullCitation": "Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286", "Include": "true"}, {"number": "22", "ReferenceId": "26910893", "FullCitation": "Bistulfi G, et al. Oncotarget (2016) pmid: 26910893", "Include": "true"}, {"number": "23", "ReferenceId": "25407435", "FullCitation": "Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435", "Include": "true"}, {"number": "24", "ReferenceId": "23816148", "FullCitation": "Maccioni L, et al. BMC Cancer (2013) pmid: 23816148", "Include": "true"}, {"number": "25", "ReferenceId": "26635288", "FullCitation": "Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288", "Include": "true"}, {"number": "26", "ReferenceId": "27960044", "FullCitation": "Lin X, et al. Cancer Sci. (2017) pmid: 27960044", "Include": "true"}, {"number": "27", "ReferenceId": "27994653", "FullCitation": "Zhi L, et al. J Cancer (2016) pmid: 27994653", "Include": "true"}, {"number": "28", "ReferenceId": "23361049", "FullCitation": "Gu F, et al. Br. J. Cancer (2013) pmid: 23361049", "Include": "true"}, {"number": "29", "ReferenceId": "33450196", "FullCitation": "Kalev P, et al. Cancer Cell (2021) pmid: 33450196", "Include": "true"}, {"number": "30", "ReferenceId": "31350521", "FullCitation": "Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521", "Include": "true"}, {"number": "31", "ReferenceId": "31257072", "FullCitation": "Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072", "Include": "true"}, {"number": "32", "ReferenceId": "31287990", "FullCitation": "Srour N, et al. Cancer Cell (2019) pmid: 31287990", "Include": "true"}, {"number": "33", "ReferenceId": "30916320", "FullCitation": "Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320", "Include": "true"}, {"number": "34", "ReferenceId": "35041419", "FullCitation": "Smith CR, et al. J Med Chem (2022) pmid: 35041419", "Include": "true"}, {"number": "35", "ReferenceId": "31040154", "FullCitation": "Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154", "Include": "true"}, {"number": "36", "ReferenceId": "29844120", "FullCitation": "Tang B, et al. Cancer Res. (2018) pmid: 29844120", "Include": "true"}, {"number": "37", "ReferenceId": "24928612", "FullCitation": "Munshi PN, et al. Oncologist (2014) pmid: 24928612", "Include": "true"}, {"number": "38", "ReferenceId": "26751376", "FullCitation": "de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376", "Include": "true"}, {"number": "39", "ReferenceId": "19478948", "FullCitation": "Lubin M, et al. PLoS ONE (2009) pmid: 19478948", "Include": "true"}, {"number": "40", "ReferenceId": "22825330", "FullCitation": "Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330", "Include": "true"}, {"number": "41", "ReferenceId": "22252602", "FullCitation": "Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602", "Include": "true"}, {"number": "42", "ReferenceId": "21301207", "FullCitation": "Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207", "Include": "true"}, {"number": "43", "ReferenceId": "21282358", "FullCitation": "Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358", "Include": "true"}, {"number": "44", "ReferenceId": "17912432", "FullCitation": "Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432", "Include": "true"}, {"number": "45", "ReferenceId": "11987241", "FullCitation": "Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241", "Include": "true"}, {"number": "46", "ReferenceId": "18618081", "FullCitation": "Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081", "Include": "true"}, {"number": "47", "ReferenceId": "35379845", "FullCitation": "Alhalabi O, et al. Nat Commun (2022) pmid: 35379845", "Include": "true"}, {"number": "48", "ReferenceId": "10582339", "FullCitation": "Int. J. Biochem. Cell Biol. (1999) pmid: 10582339", "Include": "true"}, {"number": "49", "ReferenceId": "15175998", "FullCitation": "Semin. Oncol. (2004) pmid: 15175998", "Include": "true"}, {"number": "50", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "51", "ReferenceId": "24071852", "FullCitation": "Zack TI, et al. Nat. Genet. (2013) pmid: 24071852", "Include": "true"}, {"number": "52", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "53", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "54", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "55", "ReferenceId": "21382095", "FullCitation": "Nobusawa S, et al. Neuropathology (2011) pmid: 21382095", "Include": "true"}, {"number": "56", "ReferenceId": "16021678", "FullCitation": "Joensuu H, et al. J. Pathol. (2005) pmid: 16021678", "Include": "true"}, {"number": "57", "ReferenceId": "23990986", "FullCitation": "Burford A, et al. PLoS ONE (2013) pmid: 23990986", "Include": "true"}, {"number": "58", "ReferenceId": "17504929", "FullCitation": "Holtkamp N, et al. Neuro_oncology (2007) pmid: 17504929", "Include": "true"}, {"number": "59", "ReferenceId": "17189383", "FullCitation": "Puputti M, et al. Mol. Cancer Res. (2006) pmid: 17189383", "Include": "true"}, {"number": "60", "ReferenceId": "19701495", "FullCitation": "Skardelly M, et al. Transl Oncol (2009) pmid: 19701495", "Include": "true"}, {"number": "61", "ReferenceId": "29093181", "FullCitation": "Evans EK, et al. Sci Transl Med (2017) pmid: 29093181", "Include": "true"}, {"number": "62", "ReferenceId": "27536065", "FullCitation": "Abbaspour Babaei M, et al. Drug Des Devel Ther (2016) pmid: 27536065", "Include": "true"}, {"number": "63", "ReferenceId": "27563456", "FullCitation": "Ramaswamy A, et al. J Gastrointest Oncol (2016) pmid: 27563456", "Include": "true"}, {"number": "64", "ReferenceId": "23177515", "FullCitation": "Demetri GD, et al. Lancet (2013) pmid: 23177515", "Include": "true"}, {"number": "65", "ReferenceId": "27355533", "FullCitation": "Gotlib J, et al. N. Engl. J. Med. (2016) pmid: 27355533", "Include": "true"}, {"number": "66", "ReferenceId": "28424161", "FullCitation": "Jawhar M, et al. Blood (2017) pmid: 28424161", "Include": "true"}, {"number": "67", "ReferenceId": "25031773", "FullCitation": "Xu X, et al. Int J Clin Exp Pathol (2014) pmid: 25031773", "Include": "true"}, {"number": "68", "ReferenceId": "15972446", "FullCitation": "Gotlib J, et al. Blood (2005) pmid: 15972446", "Include": "true"}, {"number": "69", "ReferenceId": "29066909", "FullCitation": "Luo C, et al. Onco Targets Ther (2017) pmid: 29066909", "Include": "true"}, {"number": "70", "ReferenceId": "35753087", "FullCitation": "Janku F, et al. ESMO Open (2022) pmid: 35753087", "Include": "true"}, {"number": "71", "ReferenceId": "22162580", "FullCitation": "Si L, et al. J. Clin. Oncol. (2012) pmid: 22162580", "Include": "true"}, {"number": "72", "ReferenceId": "20038218", "FullCitation": "Parikh SA, et al. Leuk Lymphoma (2010) pmid: 20038218", "Include": "true"}, {"number": "73", "ReferenceId": "30075827", "FullCitation": "Wei X, et al. Oncol. Res. (2019) pmid: 30075827", "Include": "true"}, {"number": "74", "ReferenceId": "23775962", "FullCitation": "Hodi FS, et al. J. Clin. Oncol. (2013) pmid: 23775962", "Include": "true"}, {"number": "75", "ReferenceId": "21642685", "FullCitation": "Carvajal RD, et al. JAMA (2011) pmid: 21642685", "Include": "true"}, {"number": "76", "ReferenceId": "21690468", "FullCitation": "Guo J, et al. J. Clin. Oncol. (2011) pmid: 21690468", "Include": "true"}, {"number": "77", "ReferenceId": "15685537", "FullCitation": "Debiec_Rychter M, et al. Gastroenterology (2005) pmid: 15685537", "Include": "true"}, {"number": "78", "ReferenceId": "19303137", "FullCitation": "Dematteo RP, et al. Lancet (2009) pmid: 19303137", "Include": "true"}, {"number": "79", "ReferenceId": "16135502", "FullCitation": "Faivre S, et al. J. Clin. Oncol. (2005) pmid: 16135502", "Include": "true"}, {"number": "80", "ReferenceId": "15659505", "FullCitation": "Hotte SJ, et al. J. Clin. Oncol. (2005) pmid: 15659505", "Include": "true"}, {"number": "81", "ReferenceId": "15350030", "FullCitation": "Alcedo JC, et al. Head Neck (2004) pmid: 15350030", "Include": "true"}, {"number": "82", "ReferenceId": "21403650", "FullCitation": "Brandwein JM, et al. Leukemia (2011) pmid: 21403650", "Include": "true"}, {"number": "83", "ReferenceId": "19904263", "FullCitation": "Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263", "Include": "true"}, {"number": "84", "ReferenceId": "26424760", "FullCitation": "Lee SJ, et al. Oncologist (2015) pmid: 26424760", "Include": "true"}, {"number": "85", "ReferenceId": "22374331", "FullCitation": "Llovet JM, et al. Clin. Cancer Res. (2012) pmid: 22374331", "Include": "true"}, {"number": "86", "ReferenceId": "23058498", "FullCitation": "Zhang HL, et al. Clin Genitourin Cancer (2013) pmid: 23058498", "Include": "true"}, {"number": "87", "ReferenceId": "25450081", "FullCitation": "Seino S, et al. Gastroenterology (2014) pmid: 25450081", "Include": "true"}, {"number": "88", "ReferenceId": "18846437", "FullCitation": "Li XF, et al. Med. Oncol. (2009) pmid: 18846437", "Include": "true"}, {"number": "89", "ReferenceId": "22261812", "FullCitation": "Minor DR, et al. Clin. Cancer Res. (2012) pmid: 22261812", "Include": "true"}, {"number": "90", "ReferenceId": "23114504", "FullCitation": "Mahipal A, et al. Melanoma Res. (2012) pmid: 23114504", "Include": "true"}, {"number": "91", "ReferenceId": "18483217", "FullCitation": "Andrae J, et al. Genes Dev. (2008) pmid: 18483217", "Include": "true"}, {"number": "92", "ReferenceId": "26700815", "FullCitation": "Flavahan WA, et al. Nature (2016) pmid: 26700815", "Include": "true"}, {"number": "93", "ReferenceId": "26787600", "FullCitation": "Roszik J, et al. Sci Rep (2016) pmid: 26787600", "Include": "true"}, {"number": "94", "ReferenceId": "20129251", "FullCitation": "Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251", "Include": "true"}, {"number": "95", "ReferenceId": "27582545", "FullCitation": "Koschmann C, et al. Oncotarget (2016) pmid: 27582545", "Include": "true"}, {"number": "96", "ReferenceId": "23438035", "FullCitation": "Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035", "Include": "true"}, {"number": "97", "ReferenceId": "22389665", "FullCitation": "Puget S, et al. PLoS ONE (2012) pmid: 22389665", "Include": "true"}, {"number": "98", "ReferenceId": "23242283", "FullCitation": "Motomura K, et al. J. Neuropathol. Exp. Neurol. (2013) pmid: 23242283", "Include": "true"}, {"number": "99", "ReferenceId": "23412337", "FullCitation": "Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337", "Include": "true"}, {"number": "100", "ReferenceId": "23074200", "FullCitation": "Alentorn A, et al. Neuro_oncology (2012) pmid: 23074200", "Include": "true"}, {"number": "101", "ReferenceId": "29888103", "FullCitation": "Song K, et al. Am J Cancer Res (2018) pmid: 29888103", "Include": "true"}, {"number": "102", "ReferenceId": "22323597", "FullCitation": "Szerlip NJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22323597", "Include": "true"}, {"number": "103", "ReferenceId": "22806436", "FullCitation": "Arefi M, et al. Int. J. Hematol. (2012) pmid: 22806436", "Include": "true"}, {"number": "104", "ReferenceId": "17666373", "FullCitation": "Baccarani M, et al. Haematologica (2007) pmid: 17666373", "Include": "true"}, {"number": "105", "ReferenceId": "22718859", "FullCitation": "Cassier PA, et al. Clin. Cancer Res. (2012) pmid: 22718859", "Include": "true"}, {"number": "106", "ReferenceId": "25658984", "FullCitation": "Chalmers ZR, et al. Blood Cancer J (2015) pmid: 25658984", "Include": "true"}, {"number": "107", "ReferenceId": "12660384", "FullCitation": "Cools J, et al. N. Engl. J. Med. (2003) pmid: 12660384", "Include": "true"}, {"number": "108", "ReferenceId": "17555450", "FullCitation": "Curtis CE, et al. Br. J. Haematol. (2007) pmid: 17555450", "Include": "true"}, {"number": "109", "ReferenceId": "15010069", "FullCitation": "Debiec_Rychter M, et al. Eur. J. Cancer (2004) pmid: 15010069", "Include": "true"}, {"number": "110", "ReferenceId": "20473908", "FullCitation": "Dileo P, et al. Int. J. Cancer (2011) pmid: 20473908", "Include": "true"}, {"number": "111", "ReferenceId": "24638008", "FullCitation": "Fanta PT, et al. J. Clin. Oncol. (2015) pmid: 24638008", "Include": "true"}, {"number": "112", "ReferenceId": "16406018", "FullCitation": "Florian S, et al. Leuk. Res. (2006) pmid: 16406018", "Include": "true"}, {"number": "113", "ReferenceId": "27051816", "FullCitation": "Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816", "Include": "true"}, {"number": "114", "ReferenceId": "12808148", "FullCitation": "Griffin JH, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808148", "Include": "true"}, {"number": "115", "ReferenceId": "14645423", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423", "Include": "true"}, {"number": "116", "ReferenceId": "19120352", "FullCitation": "Helbig G, et al. Br. J. Haematol. (2009) pmid: 19120352", "Include": "true"}, {"number": "117", "ReferenceId": "24009127", "FullCitation": "Helbig G, et al. Am. J. Hematol. (2014) pmid: 24009127", "Include": "true"}, {"number": "118", "ReferenceId": "21093052", "FullCitation": "Hus M, et al. Leuk. Res. (2011) pmid: 21093052", "Include": "true"}, {"number": "119", "ReferenceId": "20303172", "FullCitation": "Ikezoe T, et al. Leuk. Res. (2010) pmid: 20303172", "Include": "true"}, {"number": "120", "ReferenceId": "19735261", "FullCitation": "Intermesoli T, et al. Br. J. Haematol. (2009) pmid: 19735261", "Include": "true"}, {"number": "121", "ReferenceId": "19013640", "FullCitation": "Jain N, et al. Leuk. Res. (2009) pmid: 19013640", "Include": "true"}, {"number": "122", "ReferenceId": "17299092", "FullCitation": "Jovanovic JV, et al. Blood (2007) pmid: 17299092", "Include": "true"}, {"number": "123", "ReferenceId": "22150077", "FullCitation": "Kang HJ, et al. Acta Oncol (2012) pmid: 22150077", "Include": "true"}, {"number": "124", "ReferenceId": "14504092", "FullCitation": "Klion AD, et al. Blood (2004) pmid: 14504092", "Include": "true"}, {"number": "125", "ReferenceId": "19192229", "FullCitation": "Kobayashi M, et al. Respirology (2009) pmid: 19192229", "Include": "true"}, {"number": "126", "ReferenceId": "24635438", "FullCitation": "Koc\u00e1kov\u00e1 I, et al. Klin Onkol (2014) pmid: 24635438", "Include": "true"}, {"number": "127", "ReferenceId": "18950453", "FullCitation": "Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453", "Include": "true"}, {"number": "128", "ReferenceId": "22645636", "FullCitation": "Murayama Y, et al. World J Gastrointest Oncol (2012) pmid: 22645636", "Include": "true"}, {"number": "129", "ReferenceId": "19910029", "FullCitation": "Ogbogu PU, et al. J. Allergy Clin. Immunol. (2009) pmid: 19910029", "Include": "true"}, {"number": "130", "ReferenceId": "16856885", "FullCitation": "Ohnishi H, et al. Br. J. Haematol. (2006) pmid: 16856885", "Include": "true"}, {"number": "131", "ReferenceId": "12842979", "FullCitation": "Pardanani A, et al. Blood (2003) pmid: 12842979", "Include": "true"}, {"number": "132", "ReferenceId": "15284118", "FullCitation": "Pardanani A, et al. Blood (2004) pmid: 15284118", "Include": "true"}, {"number": "133", "ReferenceId": "27120808", "FullCitation": "Qu SQ, et al. Oncotarget (2016) pmid: 27120808", "Include": "true"}, {"number": "134", "ReferenceId": "16498388", "FullCitation": "Score J, et al. Leukemia (2006) pmid: 16498388", "Include": "true"}, {"number": "135", "ReferenceId": "24669761", "FullCitation": "Shah S, et al. J Hematol Oncol (2014) pmid: 24669761", "Include": "true"}, {"number": "136", "ReferenceId": "26319757", "FullCitation": "Sugimoto Y, et al. Cancer Genet (2015) pmid: 26319757", "Include": "true"}, {"number": "137", "ReferenceId": "20609486", "FullCitation": "Volz HC, et al. Int. J. Cardiol. (2011) pmid: 20609486", "Include": "true"}, {"number": "138", "ReferenceId": "15618966", "FullCitation": "von Bubnoff N, et al. Leukemia (2005) pmid: 15618966", "Include": "true"}, {"number": "139", "ReferenceId": "16845659", "FullCitation": "Walz C, et al. Genes Chromosomes Cancer (2006) pmid: 16845659", "Include": "true"}, {"number": "140", "ReferenceId": "26130666", "FullCitation": "Yoo C, et al. Cancer Res Treat (2016) pmid: 26130666", "Include": "true"}, {"number": "141", "ReferenceId": "23157309", "FullCitation": "Al_Riyami AZ, et al. Leuk. Lymphoma (2013) pmid: 23157309", "Include": "true"}, {"number": "142", "ReferenceId": "16645167", "FullCitation": "Lierman E, et al. Blood (2006) pmid: 16645167", "Include": "true"}, {"number": "143", "ReferenceId": "19212337", "FullCitation": "Lierman E, et al. Leukemia (2009) pmid: 19212337", "Include": "true"}, {"number": "144", "ReferenceId": "21818111", "FullCitation": "Metzgeroth G, et al. Leukemia (2012) pmid: 21818111", "Include": "true"}, {"number": "145", "ReferenceId": "22294526", "FullCitation": "Roubaud G, et al. Ann. Oncol. (2012) pmid: 22294526", "Include": "true"}, {"number": "146", "ReferenceId": "20972453", "FullCitation": "von Bubnoff N, et al. Oncogene (2011) pmid: 20972453", "Include": "true"}, {"number": "147", "ReferenceId": "24057647", "FullCitation": "Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2013) pmid: 24057647", "Include": "true"}, {"number": "148", "ReferenceId": "20832858", "FullCitation": "Tabouret E, et al. Leuk. Res. (2011) pmid: 20832858", "Include": "true"}, {"number": "149", "ReferenceId": "18794084", "FullCitation": "Dewaele B, et al. Clin. Cancer Res. (2008) pmid: 18794084", "Include": "true"}, {"number": "150", "ReferenceId": "17087936", "FullCitation": "Weisberg E, et al. Gastroenterology (2006) pmid: 17087936", "Include": "true"}, {"number": "151", "ReferenceId": "26396737", "FullCitation": "Brohl AS, et al. Clin Sarcoma Res (2015) pmid: 26396737", "Include": "true"}, {"number": "152", "ReferenceId": "28031906", "FullCitation": "Grellety T, et al. Future Sci OA (2015) pmid: 28031906", "Include": "true"}, {"number": "153", "ReferenceId": "25905001", "FullCitation": "Koll\u00e0r A, et al. Clin Sarcoma Res (2014) pmid: 25905001", "Include": "true"}, {"number": "154", "ReferenceId": "18337605", "FullCitation": "Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605", "Include": "true"}, {"number": "155", "ReferenceId": "20942962", "FullCitation": "Foster JM, et al. World J Surg Oncol (2010) pmid: 20942962", "Include": "true"}, {"number": "156", "ReferenceId": "18193092", "FullCitation": "Cai CQ, et al. Oncogene (2008) pmid: 18193092", "Include": "true"}, {"number": "157", "ReferenceId": "15735034", "FullCitation": "Stabile LP, et al. Cancer Res. (2005) pmid: 15735034", "Include": "true"}, {"number": "158", "ReferenceId": "17409930", "FullCitation": "Zhang W, et al. J Thorac Oncol (2006) pmid: 17409930", "Include": "true"}, {"number": "159", "ReferenceId": "22258476", "FullCitation": "Siegfried JM, et al. J Thorac Oncol (2012) pmid: 22258476", "Include": "true"}, {"number": "160", "ReferenceId": "24743239", "FullCitation": "U M, et al. PLoS Comput. Biol. (2014) pmid: 24743239", "Include": "true"}, {"number": "161", "ReferenceId": "24894453", "FullCitation": "Cho J, et al. Mol. Cancer (2014) pmid: 24894453", "Include": "true"}, {"number": "162", "ReferenceId": "19726454", "FullCitation": "Hama T, et al. Oncologist (2009) pmid: 19726454", "Include": "true"}, {"number": "163", "ReferenceId": "19671738", "FullCitation": "Tam IY, et al. Mol. Cancer Ther. (2009) pmid: 19671738", "Include": "true"}, {"number": "164", "ReferenceId": "19147750", "FullCitation": "Kancha RK, et al. Clin. Cancer Res. (2009) pmid: 19147750", "Include": "true"}, {"number": "165", "ReferenceId": "16205628", "FullCitation": "Chen YR, et al. Oncogene (2006) pmid: 16205628", "Include": "true"}, {"number": "166", "ReferenceId": "17177598", "FullCitation": "Lee JC, et al. PLoS Med. (2006) pmid: 17177598", "Include": "true"}, {"number": "167", "ReferenceId": "24212795", "FullCitation": "Ymer SI, et al. Cancers (Basel) (2011) pmid: 24212795", "Include": "true"}, {"number": "168", "ReferenceId": "19789313", "FullCitation": "Razis E, et al. Clin. Cancer Res. (2009) pmid: 19789313", "Include": "true"}, {"number": "169", "ReferenceId": "21532887", "FullCitation": "Wang H, et al. Neoplasia (2011) pmid: 21532887", "Include": "true"}, {"number": "170", "ReferenceId": "31290142", "FullCitation": "Kim N, et al. Int. J. Cancer (2019) pmid: 31290142", "Include": "true"}, {"number": "171", "ReferenceId": "32190291", "FullCitation": "Sueangoen N, et al. Cell Biosci (2020) pmid: 32190291", "Include": "true"}, {"number": "172", "ReferenceId": "31585087", "FullCitation": "Lundby A, et al. Cell (2019) pmid: 31585087", "Include": "true"}, {"number": "173", "ReferenceId": "31263031", "FullCitation": "Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031", "Include": "true"}, {"number": "174", "ReferenceId": "26824661", "FullCitation": "Ceccarelli M, et al. Cell (2016) pmid: 26824661", "Include": "true"}, {"number": "175", "ReferenceId": "28472509", "FullCitation": "Thomas AA, et al. Neuro_oncology (2017) pmid: 28472509", "Include": "true"}, {"number": "176", "ReferenceId": "22588883", "FullCitation": "Vivanco I, et al. Cancer Discov (2012) pmid: 22588883", "Include": "true"}, {"number": "177", "ReferenceId": "20702468", "FullCitation": "Srividya MR, et al. J. Clin. Pathol. (2010) pmid: 20702468", "Include": "true"}, {"number": "178", "ReferenceId": "20888234", "FullCitation": "Das P, et al. J Clin Neurosci (2011) pmid: 20888234", "Include": "true"}, {"number": "179", "ReferenceId": "11504770", "FullCitation": "Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770", "Include": "true"}, {"number": "180", "ReferenceId": "22285168", "FullCitation": "Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168", "Include": "true"}, {"number": "181", "ReferenceId": "24263064", "FullCitation": "Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064", "Include": "true"}, {"number": "182", "ReferenceId": "32673682", "FullCitation": "Hayashi T, et al. Hum Pathol (2020) pmid: 32673682", "Include": "true"}, {"number": "183", "ReferenceId": "29780256", "FullCitation": "Cao L, et al. Onco Targets Ther (2018) pmid: 29780256", "Include": "true"}, {"number": "184", "ReferenceId": "21422421", "FullCitation": "Yang TY, et al. J. Clin. Oncol. (2011) pmid: 21422421", "Include": "true"}, {"number": "185", "ReferenceId": "23816960", "FullCitation": "Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960", "Include": "true"}, {"number": "186", "ReferenceId": "30127622", "FullCitation": "Qin BD, et al. Onco Targets Ther (2018) pmid: 30127622", "Include": "true"}, {"number": "187", "ReferenceId": "27131295", "FullCitation": "Frega S, et al. J Thorac Oncol (2016) pmid: 27131295", "Include": "true"}, {"number": "188", "ReferenceId": "33116645", "FullCitation": "Long X, et al. Onco Targets Ther (2020) pmid: 33116645", "Include": "true"}, {"number": "189", "ReferenceId": "29864379", "FullCitation": "Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379", "Include": "true"}, {"number": "190", "ReferenceId": "25923549", "FullCitation": "J\u00e4nne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549", "Include": "true"}, {"number": "191", "ReferenceId": "32749686", "FullCitation": "Hong MH, et al. Cancer (2020) pmid: 32749686", "Include": "true"}, {"number": "192", "ReferenceId": "26462025", "FullCitation": "Kim HS, et al. Oncotarget (2015) pmid: 26462025", "Include": "true"}, {"number": "193", "ReferenceId": "25424851", "FullCitation": "Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851", "Include": "true"}, {"number": "194", "ReferenceId": "32303840", "FullCitation": "Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840", "Include": "true"}, {"number": "195", "ReferenceId": "29734047", "FullCitation": "Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047", "Include": "true"}, {"number": "196", "ReferenceId": "32923886", "FullCitation": "Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886", "Include": "true"}, {"number": "197", "ReferenceId": "31769726", "FullCitation": "Makhlin I, et al. CNS Oncol (2019) pmid: 31769726", "Include": "true"}, {"number": "198", "ReferenceId": "33940677", "FullCitation": "Goyal A, et al. World Neurosurg (2021) pmid: 33940677", "Include": "true"}, {"number": "199", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "200", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "201", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "202", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "203", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "204", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "205", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "206", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "207", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "208", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "209", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "210", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "211", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "212", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "213", "ReferenceId": "22015685", "FullCitation": "Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685", "Include": "true"}, {"number": "214", "ReferenceId": "9282118", "FullCitation": "Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118", "Include": "true"}, {"number": "215", "ReferenceId": "7605428", "FullCitation": "Kim NW, et al. Science (1994) pmid: 7605428", "Include": "true"}, {"number": "216", "ReferenceId": "10647931", "FullCitation": "Hanahan D, et al. Cell (2000) pmid: 10647931", "Include": "true"}, {"number": "217", "ReferenceId": "23348503", "FullCitation": "Horn S, et al. Science (2013) pmid: 23348503", "Include": "true"}, {"number": "218", "ReferenceId": "23348506", "FullCitation": "Huang FW, et al. Science (2013) pmid: 23348506", "Include": "true"}, {"number": "219", "ReferenceId": "23887589", "FullCitation": "Vinagre J, et al. Nat Commun (2013) pmid: 23887589", "Include": "true"}, {"number": "220", "ReferenceId": "23530248", "FullCitation": "Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248", "Include": "true"}, {"number": "221", "ReferenceId": "24722048", "FullCitation": "Killela PJ, et al. Oncotarget (2014) pmid: 24722048", "Include": "true"}, {"number": "222", "ReferenceId": "23955565", "FullCitation": "Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565", "Include": "true"}, {"number": "223", "ReferenceId": "23603989", "FullCitation": "Liu X, et al. Cell Cycle (2013) pmid: 23603989", "Include": "true"}, {"number": "224", "ReferenceId": "24154961", "FullCitation": "Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961", "Include": "true"}, {"number": "225", "ReferenceId": "23764841", "FullCitation": "Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841", "Include": "true"}, {"number": "226", "ReferenceId": "24217890", "FullCitation": "Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890", "Include": "true"}, {"number": "227", "ReferenceId": "27245281", "FullCitation": "Nat Rev Clin Oncol (2017) pmid: 27245281", "Include": "true"}, {"number": "228", "ReferenceId": "29249395", "FullCitation": "Duperret EK, et al. Mol Ther (2018) pmid: 29249395", "Include": "true"}, {"number": "229", "ReferenceId": "25467017", "FullCitation": "Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017", "Include": "true"}, {"number": "230", "ReferenceId": "33293629", "FullCitation": "Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629", "Include": "true"}, {"number": "231", "ReferenceId": "34185076", "FullCitation": "Louis DN, et al. Neuro Oncol (2021) pmid: 34185076", "Include": "true"}, {"number": "232", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "233", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "234", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "235", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "236", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "237", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "238", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "239", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "240", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "241", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "242", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "243", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "244", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "245", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "246", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "247", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "248", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "249", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "250", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "251", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "252", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "253", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "254", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "255", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "256", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "257", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "258", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "259", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "260", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "261", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "262", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "263", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "264", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "265", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "266", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "267", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "268", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "269", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "270", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "271", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "272", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "273", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "274", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "275", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "276", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "277", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "278", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "279", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "280", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "281", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "282", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "283", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "284", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "285", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "286", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "287", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "288", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "289", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "290", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "291", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "292", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "293", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "294", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "295", "ReferenceId": "16909113", "FullCitation": "Weber RG, et al. Oncogene (2007) pmid: 16909113", "Include": "true"}, {"number": "296", "ReferenceId": "11303791", "FullCitation": "Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791", "Include": "true"}, {"number": "297", "ReferenceId": "11489817", "FullCitation": "Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817", "Include": "true"}, {"number": "298", "ReferenceId": "21713760", "FullCitation": "Feng J, et al. Cancer (2012) pmid: 21713760", "Include": "true"}, {"number": "299", "ReferenceId": "21636552", "FullCitation": "Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552", "Include": "true"}, {"number": "300", "ReferenceId": "21843312", "FullCitation": "Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312", "Include": "true"}, {"number": "301", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "302", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "303", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "304", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "305", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "306", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "307", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "308", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "309", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "310", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "311", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "312", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "313", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "314", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "315", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "316", "ReferenceId": "31700061", "FullCitation": "Su D, et al. Nat Commun (2019) pmid: 31700061", "Include": "true"}, {"number": "317", "ReferenceId": "32923894", "FullCitation": "Tramontana TF, et al. JCO Precis Oncol (2020) pmid: 32923894", "Include": "true"}, {"number": "318", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "319", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "320", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "321", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "322", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "323", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "324", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "325", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "326", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "327", "ReferenceId": "16282176", "FullCitation": "Mellinghoff IK, et al. N. Engl. J. Med. (2005) pmid: 16282176", "Include": "true"}, {"number": "328", "ReferenceId": "19075262", "FullCitation": "Prados MD, et al. J. Clin. Oncol. (2009) pmid: 19075262", "Include": "true"}, {"number": "329", "ReferenceId": "22946346", "FullCitation": "Kesavabhotla K, et al. J. Exp. Ther. Oncol. (2012) pmid: 22946346", "Include": "true"}, {"number": "330", "ReferenceId": "23328813", "FullCitation": "Peereboom DM, et al. Neuro_oncology (2013) pmid: 23328813", "Include": "true"}, {"number": "331", "ReferenceId": "29320312", "FullCitation": "Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312", "Include": "true"}, {"number": "332", "ReferenceId": "29998897", "FullCitation": "Nie KK, et al. Chin Med J (Engl) (2018) pmid: 29998897", "Include": "true"}, {"number": "333", "ReferenceId": "20493771", "FullCitation": "Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771", "Include": "true"}, {"number": "334", "ReferenceId": "31194613", "FullCitation": "Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613", "Include": "true"}, {"number": "335", "ReferenceId": "22056888", "FullCitation": "Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888", "Include": "true"}, {"number": "336", "ReferenceId": "24335106", "FullCitation": "Hughes TP, et al. Blood (2014) pmid: 24335106", "Include": "true"}, {"number": "337", "ReferenceId": "24650752", "FullCitation": "Takahashi N, et al. Biomark Res (2014) pmid: 24650752", "Include": "true"}, {"number": "338", "ReferenceId": "22357255", "FullCitation": "Reichardt P, et al. Ann. Oncol. (2012) pmid: 22357255", "Include": "true"}, {"number": "339", "ReferenceId": "22119758", "FullCitation": "Cauchi C, et al. Cancer Chemother. Pharmacol. (2012) pmid: 22119758", "Include": "true"}, {"number": "340", "ReferenceId": "22662203", "FullCitation": "Villar VH, et al. PLoS ONE (2012) pmid: 22662203", "Include": "true"}, {"number": "341", "ReferenceId": "25695690", "FullCitation": "Carvajal RD, et al. Clin. Cancer Res. (2015) pmid: 25695690", "Include": "true"}, {"number": "342", "ReferenceId": "26002753", "FullCitation": "Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 26002753", "Include": "true"}, {"number": "343", "ReferenceId": "25882987", "FullCitation": "Blay JY, et al. Lancet Oncol. (2015) pmid: 25882987", "Include": "true"}, {"number": "344", "ReferenceId": "26722383", "FullCitation": "Kajimoto N, et al. Int J Clin Exp Pathol (2015) pmid: 26722383", "Include": "true"}, {"number": "345", "ReferenceId": "25221952", "FullCitation": "Sako H, et al. PLoS ONE (2014) pmid: 25221952", "Include": "true"}, {"number": "346", "ReferenceId": "17353924", "FullCitation": "Franceschi E, et al. Br. J. Cancer (2007) pmid: 17353924", "Include": "true"}, {"number": "347", "ReferenceId": "23182702", "FullCitation": "Chakravarti A, et al. Int. J. Radiat. Oncol. Biol. Phys. (2013) pmid: 23182702", "Include": "true"}, {"number": "348", "ReferenceId": "21471286", "FullCitation": "Hegi ME, et al. Mol. Cancer Ther. (2011) pmid: 21471286", "Include": "true"}, {"number": "349", "ReferenceId": "22370314", "FullCitation": "Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314", "Include": "true"}, {"number": "350", "ReferenceId": "20573926", "FullCitation": "Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926", "Include": "true"}, {"number": "351", "ReferenceId": "20022809", "FullCitation": "Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809", "Include": "true"}, {"number": "352", "ReferenceId": "19692680", "FullCitation": "Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680", "Include": "true"}, {"number": "353", "ReferenceId": "25329826", "FullCitation": "Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826", "Include": "true"}, {"number": "354", "ReferenceId": "25546556", "FullCitation": "Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556", "Include": "true"}, {"number": "355", "ReferenceId": "30255937", "FullCitation": "Wang J, et al. Int. J. Cancer (2019) pmid: 30255937", "Include": "true"}, {"number": "356", "ReferenceId": "26398831", "FullCitation": "Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831", "Include": "true"}, {"number": "357", "ReferenceId": "25674429", "FullCitation": "Hassler MR, et al. Springerplus (2014) pmid: 25674429", "Include": "true"}, {"number": "358", "ReferenceId": "22371319", "FullCitation": "Reardon DA, et al. Cancer (2012) pmid: 22371319", "Include": "true"}, {"number": "359", "ReferenceId": "16624552", "FullCitation": "Debiec_Rychter M, et al. Eur. J. Cancer (2006) pmid: 16624552", "Include": "true"}, {"number": "360", "ReferenceId": "16570351", "FullCitation": "Kamenz T, et al. World J. Gastroenterol. (2006) pmid: 16570351", "Include": "true"}, {"number": "361", "ReferenceId": "15650049", "FullCitation": "Wang YY, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15650049", "Include": "true"}, {"number": "362", "ReferenceId": "35636696", "FullCitation": "Kenmotsu H, et al. J Thorac Oncol (2022) pmid: 35636696", "Include": "true"}, {"number": "363", "ReferenceId": "32139298", "FullCitation": "Oxnard GR, et al. Ann. Oncol. (2020) pmid: 32139298", "Include": "true"}, {"number": "364", "ReferenceId": "31825714", "FullCitation": "Cho JH, et al. J. Clin. Oncol. (2019) pmid: 31825714", "Include": "true"}, {"number": "365", "ReferenceId": "29151359", "FullCitation": "Soria JC, et al. N. Engl. J. Med. (2018) pmid: 29151359", "Include": "true"}, {"number": "366", "ReferenceId": "31751012", "FullCitation": "Ramalingam SS, et al. N. Engl. J. Med. (2019) pmid: 31751012", "Include": "true"}, {"number": "367", "ReferenceId": "34498213", "FullCitation": "Cardona AF, et al. J Neurooncol (2021) pmid: 34498213", "Include": "true"}, {"number": "368", "ReferenceId": "33318755", "FullCitation": "Alanazi A, et al. Lung Cancer Manag (2020) pmid: 33318755", "Include": "true"}, {"number": "369", "ReferenceId": "22832897", "FullCitation": "Pan E, et al. J. Neurooncol. (2012) pmid: 22832897", "Include": "true"}, {"number": "370", "ReferenceId": "23086433", "FullCitation": "Kreisl TN, et al. J. Neurooncol. (2013) pmid: 23086433", "Include": "true"}, {"number": "371", "ReferenceId": "24424564", "FullCitation": "Bala\u00f1a C, et al. Target Oncol (2014) pmid: 24424564", "Include": "true"}, {"number": "372", "ReferenceId": "24311637", "FullCitation": "Hutterer M, et al. Neuro_oncology (2014) pmid: 24311637", "Include": "true"}, {"number": "373", "ReferenceId": "18955458", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458", "Include": "true"}, {"number": "374", "ReferenceId": "26264378", "FullCitation": "Buchbinder EI, et al. Cancer (2015) pmid: 26264378", "Include": "true"}, {"number": "375", "ReferenceId": "26772734", "FullCitation": "Reichardt P, et al. BMC Cancer (2016) pmid: 26772734", "Include": "true"}, {"number": "376", "ReferenceId": "27073655", "FullCitation": "Hirai F, et al. Mol Clin Oncol (2016) pmid: 27073655", "Include": "true"}, {"number": "377", "ReferenceId": "20435347", "FullCitation": "Goemans BF, et al. Leuk. Res. (2010) pmid: 20435347", "Include": "true"}, {"number": "378", "ReferenceId": "23898124", "FullCitation": "Zustovich F, et al. Anticancer Res. (2013) pmid: 23898124", "Include": "true"}, {"number": "379", "ReferenceId": "20443129", "FullCitation": "Reardon DA, et al. J. Neurooncol. (2011) pmid: 20443129", "Include": "true"}, {"number": "380", "ReferenceId": "23099651", "FullCitation": "Lee EQ, et al. Neuro_oncology (2012) pmid: 23099651", "Include": "true"}, {"number": "381", "ReferenceId": "24786603", "FullCitation": "Hottinger AF, et al. Br. J. Cancer (2014) pmid: 24786603", "Include": "true"}, {"number": "382", "ReferenceId": "24803676", "FullCitation": "Karajannis MA, et al. Neuro_oncology (2014) pmid: 24803676", "Include": "true"}, {"number": "383", "ReferenceId": "18936790", "FullCitation": "Quint\u00e1s_Cardama A, et al. Nat Clin Pract Oncol (2008) pmid: 18936790", "Include": "true"}, {"number": "384", "ReferenceId": "19461405", "FullCitation": "Bisagni G, et al. J Thorac Oncol (2009) pmid: 19461405", "Include": "true"}, {"number": "385", "ReferenceId": "20372153", "FullCitation": "Handolias D, et al. Br. J. Cancer (2010) pmid: 20372153", "Include": "true"}, {"number": "386", "ReferenceId": "20970876", "FullCitation": "Di\u015fel U, et al. Lung Cancer (2011) pmid: 20970876", "Include": "true"}, {"number": "387", "ReferenceId": "22270258", "FullCitation": "Park SH, et al. Invest New Drugs (2012) pmid: 22270258", "Include": "true"}, {"number": "388", "ReferenceId": "24855380", "FullCitation": "Catania C, et al. Onco Targets Ther (2014) pmid: 24855380", "Include": "true"}, {"number": "389", "ReferenceId": "17699867", "FullCitation": "Guo T, et al. Clin. Cancer Res. (2007) pmid: 17699867", "Include": "true"}, {"number": "390", "ReferenceId": "18483300", "FullCitation": "Hu S, et al. Mol. Cancer Ther. (2008) pmid: 18483300", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_01_12 03:04:41", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "560x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "8 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain glioblastoma (GBM)", "flowcell_analysis": "2000026857", "gender": "male", "pathology_diagnosis": "Glioblastoma", "percent_tumor_nuclei": "40", "pipeline_version": "v3.18.0", "purity_assessment": "20.5", "specimen": "ORD_1537947_01*US1470784.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1537947_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "564.67", "name": "SQ_US1470784.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.1577", "cds_effect": "3002G>A", "depth": "704", "equivocal": "false", "functional_effect": "missense", "gene": "BRIP1", "percent_reads": "15.77", "position": "chr17:59761405", "protein_effect": "S1001N", "status": "unknown", "strand": "_", "transcript": "NM_032043", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.2947", "cds_effect": "455T>A", "depth": "509", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "29.47", "position": "chr10:89692971", "protein_effect": "L152Q", "status": "unknown", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.4941", "cds_effect": "80G>A", "depth": "338", "equivocal": "false", "functional_effect": "missense", "gene": "CCNE1", "percent_reads": "49.41", "position": "chr19:30303652", "protein_effect": "R27H", "status": "unknown", "strand": "+", "transcript": "NM_001238", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.4844", "cds_effect": "1226_1228delGAG", "depth": "514", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "MRE11A", "percent_reads": "48.44", "position": "chr11:94194199", "protein_effect": "G409del", "status": "unknown", "strand": "_", "transcript": "NM_005590", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.4891", "cds_effect": "46C>T", "depth": "366", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "48.91", "position": "chr20:57428366", "protein_effect": "R16C", "status": "unknown", "strand": "+", "transcript": "NM_080425", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.0778", "cds_effect": "714C>G", "depth": "463", "equivocal": "false", "functional_effect": "missense", "gene": "MAPK1", "percent_reads": "7.78", "position": "chr22:22142993", "protein_effect": "N238K", "status": "unknown", "strand": "_", "transcript": "NM_002745", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.4658", "cds_effect": "6639C>A", "depth": "730", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "46.58", "position": "chr6:117622231", "protein_effect": "D2213E", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.4909", "cds_effect": "1415C>G", "depth": "497", "equivocal": "false", "functional_effect": "missense", "gene": "BCL6", "percent_reads": "49.09", "position": "chr3:187446273", "protein_effect": "P472R", "status": "unknown", "strand": "_", "transcript": "NM_001706", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.209", "cds_effect": "_124C>T", "depth": "134", "equivocal": "false", "functional_effect": "promoter", "gene": "TERT", "percent_reads": "20.9", "position": "chr5:1295228", "protein_effect": "promoter _124C>T", "status": "known", "strand": "_", "transcript": "NM_198253", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.0692", "cds_effect": "59_64delGCCGCA", "depth": "419", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "PIK3C2B", "percent_reads": "6.92", "position": "chr1:204438866", "protein_effect": "S20_R21del", "status": "unknown", "strand": "_", "transcript": "NM_002646", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.4706", "cds_effect": "215A>G", "depth": "527", "equivocal": "false", "functional_effect": "missense", "gene": "SGK1", "percent_reads": "47.06", "position": "chr6:134583141", "protein_effect": "H72R", "status": "unknown", "strand": "_", "transcript": "NM_001143676", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"allele_fraction": "0.0816", "cds_effect": "1787C>T", "depth": "723", "equivocal": "false", "functional_effect": "missense", "gene": "EGFR", "percent_reads": "8.16", "position": "chr7:55233037", "protein_effect": "P596L", "status": "known", "strand": "+", "transcript": "NM_005228", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "16", "equivocal": "false", "gene": "PDGFRA", "number_of_exons": "22 of 22", "position": "chr4:55079414_55202195", "ratio": "2.48", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"copy_number": "16", "equivocal": "false", "gene": "KIT", "number_of_exons": "21 of 21", "position": "chr4:55475828_55645603", "ratio": "2.71", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:22002170_22010784", "ratio": "0.84", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "MTAP", "number_of_exons": "8 of 8", "position": "chr9:21802699_21862058", "ratio": "0.73", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21968169_21994453", "ratio": "0.83", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}]}, "rearrangements": {"rearrangement": {"description": "TGFBR2(NM_003242) rearrangement intron 4", "equivocal": "false", "in_frame": "unknown", "other_gene": "ICA1", "pos1": "chr3:30713536_30714011", "pos2": "chr7:8170601_8171240", "status": "unknown", "supporting_read_pairs": "41", "targeted_gene": "TGFBR2", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1470784.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "8.45", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}